世界のCTLA4（細胞傷害性Tリンパ球関連タンパク質4）阻害薬市場は、予測期間中に約9.81 %のCAGRで推移し、2022年から2026年の間に10億USドルの成長が見込まれています。本レポートは、総体的な分析、市場規模と予測、動向、成長推進要因、課題、および約25社のベンダーを対象とするベンダー分析を提供しています。
本レポートは、現在の世界市場シナリオ、最新動向と成長推進要因、および全体的な市場環境に関する最新の分析を提供します。本市場は、CTLA4阻害薬の高い標的親和性と特異性、および併用療法の普及により、成長が促進されています。
TechNavio社の堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されており、これに沿って、主要なCTLA4（細胞傷害性Tリンパ球関連タンパク質4）阻害薬市場ベンダーの詳細な分析を提供します
この調査は、業界の主要な参加者からの情報を含む、一次情報と二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加えて、包括的な市場とベンダー情勢が含まれています。
TechNavio社は、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析により、複数のソースからのデータの調査、統合、および集計により、市場の詳細な状況を提示します。また、業界の主要なインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは、包括的で信頼性が高く、一次および二次の広範な調査の結果です。TechNavio社の市場調査レポートは、完全な競争環境と、質的および量的調査を使用して正確な市場成長を予測する詳細なベンダー選択の調査手法と分析を提供します。
目次
Table of Contents
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding
Exhibit 02: Key Finding
Exhibit 03: Key Finding
Exhibit 04: Key Finding
Exhibit 05: Key Finding
Exhibit 06: Key Finding
Exhibit 07: Key Finding
2. Market Landscape
2.1 Market ecosystem
2.1.1 Parent Market
Exhibit 08 Parent market
Exhibit 09: Market characteristics
2.2 Value Chain Analysis
Exhibit 10: Value Chain Analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery:
2.2.2 Integration and product development:
2.2.3 Manufacturing:
2.2.4 Outbound logistics:
2.2.5 Marketing and sales:
2.2.6 Support services:
2.2.7 Innovation
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2026
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 - 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of the buyer
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of the supplier
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
Exhibit 22: Type Market share 2021 - 2026 (%)
5.2 Comparison by Type
Exhibit 23: Comparison by Type
5.3 Monotherapy - Market size and forecast 2021-2026
Exhibit 24: Monotherapy- Market size and forecast 2021-2026 ($ million)
Exhibit 25: Monotherapy - Year-over-year growth 2021-2026 (%)
5.4 Combination therapy - Market size and forecast 2021-2026
Exhibit 26: Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 27: Combination therapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Type
Exhibit 28: Market opportunity by Application
6. Customer landscape
Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
6.1 Overview
Exhibit 29: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 31: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 32: North America - Market size and forecast 2021-2026($ million)
Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe- Market size and forecast 2021-2026
Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 35: Europe- Year-over-year growth 2021-2026 (%)
7.5 Asia- Market size and forecast 2021-2026
Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Asia - Year-over-year growth 2021-2026(%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 40: Key leading countries
7.8 Market opportunity By Geographical Landscape
Exhibit 41: Market opportunity By Geographical Landscape ($ million)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 High target affinity and specificity of CTLA4 inhibitors
8.1.2 Growing popularity of combination therapy
8.1.3 Strategic alliances
8.2 Market challenges
8.2.1 Lack of approved therapies
8.2.2 Availability of substitutes
8.2.3 Stringent regulations
Exhibit 42: Impact of drivers and challenges
8.3 Market trends
8.3.1 Expansion of research indications
8.3.2 Special drug designations
8.3.3 Increasing awareness about cancer
9. Vendor Landscape
9.1 Overview
Exhibit 43: Vendor landscape
9.2 Landscape disruption
Exhibit 44: Landscape disruption
Exhibit 45: Industry Risk
9.3 Competitive Scenario
10. Vendor Analysis
10.1 Vendors covered
Exhibit 46: Vendors covered
10.2 Market positioning of vendors
Exhibit 47: Market positioning of vendors
10.3 Agenus Inc.
Exhibit 48: Agenus Inc. - Overview
Exhibit 49: Agenus Inc. - Business segments
Exhibit 50: Agenus Inc. - Key offerings
10.4 AstraZeneca Plc
Exhibit 51: AstraZeneca Plc - Overview
Exhibit 52: AstraZeneca Plc - Product and service
Exhibit 53: AstraZeneca Plc - Key offerings
10.5 BioAtla Inc.
Exhibit 54: BioAtla Inc. - Overview
Exhibit 55: BioAtla Inc. - Business segments
Exhibit 56: BioAtla Inc. - Key offerings
10.6 Bristol Myers Squibb Co.
Exhibit 57: Bristol Myers Squibb Co. - Overview
Exhibit 58: Bristol Myers Squibb Co. - Product and service
Exhibit 59: Bristol Myers Squibb Co. - Key offerings
10.7 Incyte Corp.
Exhibit 60: Incyte Corp. - Overview
Exhibit 61: Incyte Corp. - Business segments
Exhibit 62: Incyte Corp. - Key offerings
10.8 Merck and Co. Inc.
Exhibit 63: Merck and Co. Inc. - Overview
Exhibit 64: Merck and Co. Inc. - Business segments
Exhibit 65: Merck and Co. Inc. - Key offerings
Exhibit 66: Merck and Co. Inc. - Segment focus
10.9 Ono Pharmaceutical Co. Ltd.
Exhibit 67: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 68: Ono Pharmaceutical Co. Ltd. - Product and service
Exhibit 69: Ono Pharmaceutical Co. Ltd. - Key offerings
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 70: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 71: Research Methodology
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: Information sources
11.4 List of abbreviations
Exhibit 74: List of abbreviations
Exhibits
Exhibits1: Key Finding
Exhibits2: Key Finding
Exhibits3: Key Finding
Exhibits4: Key Finding
Exhibits5: Key Finding
Exhibits6: Key Finding
Exhibits7: Key Finding
Exhibits8: Parent market
Exhibits9: Market characteristics
Exhibits10: Offerings of vendors included in the market definition
Exhibits11: Market segments
Exhibits12: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
Exhibits14: Five forces analysis 2021 & 2026
Exhibits15: Bargaining power of buyers
Exhibits16: Bargaining power of suppliers
Exhibits17: Threat of new entrants
Exhibits18: Threat of substitutes
Exhibits19: Threat of rivalry
Exhibits20: Market condition - Five forces 2021
Exhibits21: Type - Market share 2021-2026 (%)
Exhibits22: Comparison by Type
Exhibits23: Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits24: Monotherapy - Year-over-year growth 2021-2026 (%)
Exhibits25: Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibits26: Combination therapy - Year-over-year growth 2021-2026 (%)
Exhibits27: Market opportunity by Type
Exhibits28: Customer landscape
Exhibits29: Market share By Geographical Landscape 2021-2026 (%)
Exhibits30: Geographic comparison
Exhibits31: North America - Market size and forecast 2021-2026 ($ million)
Exhibits32: North America - Year-over-year growth 2021-2026 (%)
Exhibits33: Europe - Market size and forecast 2021-2026 ($ million)
Exhibits34: Europe - Year-over-year growth 2021-2026 (%)
Exhibits35: Asia - Market size and forecast 2021-2026 ($ million)
Exhibits36: Asia - Year-over-year growth 2021-2026 (%)
Exhibits37: ROW - Market size and forecast 2021-2026 ($ million)
Exhibits38: ROW - Year-over-year growth 2021-2026 (%)
Exhibits39: Key leading countries
Exhibits40: Market opportunity By Geographical Landscape ($ million)
Exhibits41: Impact of drivers and challenges
Exhibits42: Vendor landscape
Exhibits43: Landscape disruption
Exhibits44: Industry risks
Exhibits45: Vendors covered
Exhibits46: Market positioning of vendors
Exhibits47: Agenus Inc. - Overview
Exhibits48: Agenus Inc. - Business segments
Exhibits49: Agenus Inc. - Key offerings
Exhibits50: Agenus Inc. - Key customers
Exhibits51: Agenus Inc. - Segment focus
Exhibits52: AstraZeneca Plc - Overview
Exhibits53: AstraZeneca Plc - Product and service
Exhibits54: AstraZeneca Plc - Key offerings
Exhibits55: AstraZeneca Plc - Key customers
Exhibits56: AstraZeneca Plc - Segment focus
Exhibits57: BioAtla Inc. - Overview
Exhibits58: BioAtla Inc. - Business segments
Exhibits59: BioAtla Inc. - Key offerings
Exhibits60: BioAtla Inc. - Key customers
Exhibits61: BioAtla Inc. - Segment focus
Exhibits62: Bristol Myers Squibb Co. - Overview
Exhibits63: Bristol Myers Squibb Co. - Product and service
Exhibits64: Bristol Myers Squibb Co. - Key offerings
Exhibits65: Bristol Myers Squibb Co. - Key customers
Exhibits66: Bristol Myers Squibb Co. - Segment focus
Exhibits67: Incyte Corp. - Overview
Exhibits68: Incyte Corp. - Business segments
Exhibits69: Incyte Corp. - Key offerings
Exhibits70: Incyte Corp. - Key customers
Exhibits71: Incyte Corp. - Segment focus
Exhibits72: Merck and Co. Inc. - Overview
Exhibits73: Merck and Co. Inc. - Business segments
Exhibits74: Merck and Co. Inc. - Key offerings
Exhibits75: Merck and Co. Inc. - Key customers
Exhibits76: Merck and Co. Inc. - Segment focus
Exhibits77: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits78: Ono Pharmaceutical Co. Ltd. - Product and service
Exhibits79: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits80: Ono Pharmaceutical Co. Ltd. - Key customers
Exhibits81: Ono Pharmaceutical Co. Ltd. - Segment focus
Exhibits82: Currency conversion rates for US$
Exhibits83: Research Methodology
Exhibits84: Validation techniques employed for market sizing
Exhibits85: Information sources
Exhibits86: List of abbreviations
